The FDA has approved Mavyret (glecaprevir and pibrentasvir), from AbbVie, tablets to treat all six genotypes of hepatitis C virus...
AbbVie announced that the FDA approved Mavyret (glecaprevir/pibrentasvir), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV)...
AbbVie announced new data for its pan-genotypic chronic hepatitis C virus (HCV) treatment, Mavyret (glecaprevir/pibrentasvir), in treatment-na�ve patients with compensated...
The FDA has issued a warning about rare cases of liver injury in HCV patients receiving either AbbVie's Mavyret (glecaprevir/pibrentasvir),...
AbbVie announced that the FDA has granted approval of Mavyret (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to...